What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?

Have you changed your practice given BMT-CTN 1506/Morpho results? Would you utilize maintenance therapy in patients who achieve MRD- remission?

1 Answer

Mednet MemberInvited Expert

Medical Oncology · University of Maryland Cancer Center

Answered on

I would offer maintenance with FLT3 inhibitor with gilteritinib (NCT02997202: MORPHO trial, not yet published), sorafenib (SORMAIN trial), or midostaurin (RADIUS trial), whichever agent is available. In my experience, gilteritinib appears to be the most tolerable. I suggest beginning maintenance as ...

Join for free or sign in to see the full answer